Literature DB >> 21471184

Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis.

N A Sutedja1, Y T van der Schouw, K Fischer, E M Sizoo, M H B Huisman, J H Veldink, L H Van den Berg.   

Abstract

OBJECTIVES: Reports of increased amyotrophic lateral sclerosis (ALS) with hyperlipidaemia and elevated plasma homocysteine levels as well as cigarette-smoking and polymorphisms in angiogenic genes suggest a role for altered vascular homeostasis in ALS pathogenesis. The authors assessed the association between vascular risk factors and ALS.
METHODS: Traditional cardiovascular risk factors (smoking, hypertension, hypercholesterolaemia, diabetes and body mass index (BMI)) and cardiovascular disease prior to ALS onset established by a questionnaire were compared in 334 patients and 538 age- and sex-matched controls. Biochemical assessments (total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), hs-CRP, and homocysteine) at diagnosis were measured in blood samples of 303 patients with ALS and compared with prospectively collected data from 2100 population-based controls.
RESULTS: Patients with ALS used cholesterol-lowering agents less frequently (OR=0.6, p=0.008) and had a lower BMI (OR=0.9, p=0.001), a lower LDL/HDL ratio (women: OR=0.5, p<0.001; men: OR=0.4, p<0.001) and lower homocysteine levels (women: OR=0.9, p=0.02; men: OR=0.9, p<0.001). The mean LDL and TC levels were significantly lower among patients with a lower functional vital capacity percentage of predicted (FVC). In the univariate analysis, a higher LDL/HDL ratio correlated with increased survival (HR=0.9, p=0.04); after adjusting for the confounders age, site and FVC, no difference was observed.
CONCLUSIONS: Vascular risk factors, measured clinically and biochemically, were not associated with increased ALS. Instead, patients reported less use of cholesterol-lowering medication and had a lower premorbid BMI and favourable lipid profile-all findings consistent with the hypothesis that a higher metabolic rate plays a role in ALS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21471184     DOI: 10.1136/jnnp.2010.236752

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  43 in total

1.  Cardiovascular disease and diagnosis of amyotrophic lateral sclerosis: A population based study.

Authors:  Marianthi-Anna Kioumourtzoglou; Ryan M Seals; Ole Gredal; Murray A Mittleman; Johnni Hansen; Marc G Weisskopf
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-07-20       Impact factor: 4.092

2.  Antecedent Disease is Less Prevalent in Amyotrophic Lateral Sclerosis.

Authors:  Cassie S Mitchell; Sabrina K Hollinger; Shivani D Goswami; Meraida A Polak; Robert H Lee; Jonathan D Glass
Journal:  Neurodegener Dis       Date:  2015-02-20       Impact factor: 2.977

Review 3.  The epidemiology of ALS: a conspiracy of genes, environment and time.

Authors:  Ammar Al-Chalabi; Orla Hardiman
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

4.  Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Study.

Authors:  Marianthi-Anna Kioumourtzoglou; Ran S Rotem; Ryan M Seals; Ole Gredal; Johnni Hansen; Marc G Weisskopf
Journal:  JAMA Neurol       Date:  2015-08       Impact factor: 18.302

5.  Hypolipidemia in patients with amyotrophic lateral sclerosis: a possible gender difference?

Authors:  Ji Won Yang; Sung-Min Kim; Hee-Juang Kim; Jee-Eun Kim; Kyung Seok Park; Seung-Hyun Kim; Kwang-Woo Lee; Jung-Joon Sung
Journal:  J Clin Neurol       Date:  2013-04-04       Impact factor: 3.077

Review 6.  Clinical diagnosis and management of amyotrophic lateral sclerosis.

Authors:  Orla Hardiman; Leonard H van den Berg; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

7.  ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.

Authors:  Hiroshi Mitsumoto; Pam Factor-Litvak; Howard Andrews; Raymond R Goetz; Leslie Andrews; Judith G Rabkin; Martin McElhiney; Jeri Nieves; Regina M Santella; Jennifer Murphy; Jonathan Hupf; Jess Singleton; David Merle; Mary Kilty; Daragh Heitzman; Richard S Bedlack; Robert G Miller; Jonathan S Katz; Dallas Forshew; Richard J Barohn; Eric J Sorenson; Bjorn Oskarsson; J Americo M Fernandes Filho; Edward J Kasarskis; Catherine Lomen-Hoerth; Tahseen Mozaffar; Yvonne D Rollins; Sharon P Nations; Andrea J Swenson; Jeremy M Shefner; Jinsy A Andrews; Boguslawa A Koczon-Jaremko
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-02-24       Impact factor: 4.092

8.  Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis.

Authors:  Sabrina Paganoni; Theodore Hyman; Amy Shui; Peggy Allred; Matthew Harms; Jingxia Liu; Nicholas Maragakis; David Schoenfeld; Hong Yu; Nazem Atassi; Merit Cudkowicz; Timothy M Miller
Journal:  Muscle Nerve       Date:  2015-06-01       Impact factor: 3.217

Review 9.  Cerebrovascular disorders: molecular insights and therapeutic opportunities.

Authors:  Erik Storkebaum; Annelies Quaegebeur; Miikka Vikkula; Peter Carmeliet
Journal:  Nat Neurosci       Date:  2011-10-26       Impact factor: 24.884

10.  Prior medical conditions and the risk of amyotrophic lateral sclerosis.

Authors:  Meinie Seelen; Perry T C van Doormaal; Anne E Visser; Mark H B Huisman; Margot H J Roozekrans; Sonja W de Jong; Anneke J van der Kooi; Marianne de Visser; Nicol C Voermans; Jan H Veldink; Leonard H van den Berg
Journal:  J Neurol       Date:  2014-07-25       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.